Impact of pyrrolidine-bispyrrole DNA minor groove binding agents and chirality on global proteomic profile in Escherichia Coli

Proteome Science

Chi-Wi Ong¹  Jingyueh Jeng²  Chun-Yu Lin¹  Ya-ting Yang¹ 

[1] Department of Chemistry, National Sun Yat-sen University, No. 70, Lienhai Rd., Kaohsiung, 80424, Taiwan;Department of Biotechnology, Chia Nan University of Pharmacy & Science, No. 60, Sec. 1, Erren Rd., Rende Dist., Tainan City, 71710, Taiwan

关键词: Protein up- and down-regulation;    Matrix-assisted laser desorption/ionization (time of flight);    Chirality;    Proteomics;    Pyrrolidine-bispyrroles;    Escherichia coli;   

Others  :  816916
DOI  :  10.1186/1477-5956-11-23

 received in 2013-01-07, accepted in 2013-05-13,  发布年份 2013

【 摘 要 】

Background

There is great interest in the design of small molecules that selectively target minor grooves of duplex DNA for controlling specific gene expression implicated in a disease. The design of chiral small molecules for rational drug design has attracted increasing attention due to the chirality of DNA. Yet, there is limited research on the chirality effect of minor groove binders on DNA interaction, especially at the protein expression level. This paper is an attempt to illustrate that DNA binding affinity might not provide a full picture on the biological activities. Drug interacting at the genomic level can be translated to the proteomic level. Here we have illustrated that although the chiral bispyrrole-pyrrolidine-oligoamides, PySSPy and PyRSPy, showed low binding affinity to DNA, their influence at the proteomic level is significant. More importantly, the chirality also plays a role. Two-dimensional proteomic profile to identify the differentially expressed protein in Escherichia coli DH5α (E coli DH5α) were investigated.

Results

E coli DH5α incubated with the chiral PySSPy and PyRSPy, diastereomeric at the pyrrolidine ring, showed differential expression of eighteen proteins as observed through two dimensional proteomic profiling. These eighteen proteins identified by MALDI_TOF/TOF MS include antioxidant defense, DNA protection, protein synthesis, chaperone, and stress response proteins. No statistically significant toxicity was observed at the tested drug concentrations as measured via MTT assay.

Conclusion

The current results showed that the chiral PySSPy and PyRSPy impact on the proteomic profiling of E coli DH5α, implicating the importance of drug chirality on biological activities at the molecular level.

【 授权许可】

   
2013 Yang et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

【 参考文献 】

• [1]Turner PR, Denny WA: The genome as a drug target: sequence specific minor groove binding ligands. Curr Drug Targets 2000, 1:1-14.
• [2]Neidle S: DNA minor-groove recognition by small molecules. Nat Prod Rep 2001, 18:291-309.
• [3]Hurley LH: (Ed): Sequence specificity of drugs that interact with DNA in the minor groove. In Advances in DNA Sequence-Specific Agents. 1992, 1:217-360.
• [4]Hurley LH: Chaires JB (Eds): Sequence Specificity of DNA Interactive Drugs. In Advances in DNA Sequence Specific Agents. 1996, 2:141-256.
• [5]Propst CL, Perun TJE: Nucleic Acid Targeted Drug Design. New York, NY: Marcel Dekker; 1992.
• [6]Lang D, Stamminger T: Minor groove contacts are essential for an interaction of the human cytomegalovirus IE2 protein with its DNA target. Nucleic Acids Res 1994, 22:3331-3338.
• [7]Reddy BS, Sondhi SM, Lown JW: Synthetic DNA minor groove-binding drugs. Pharmacol Ther 1999, 84:1-111.
• [8]Valíka M, Malinab J, Paliveca L, Foltýnováa J, Tkadlecováa M, Urbanovác M, Brabecb V, Krála V: Tröger's base scaffold in racemic and chiral fashion as a spacer for bisdistamycin formation. Synthesis and DNA binding study 2006, 62:8591-8600.
• [9]Herman DM, Baird EE, Dervan PB: Stereochemical Control of the DNA Binding Affinity, Sequence Specificity, and Orientation Preference of Chiral Hairpin Polyamides in the Minor Groove. J Am Chem Soc 1998, 120:1382-1391.
• [10]Lin C-Y, Yang Y-T, Ong C-W: Synthesis of Chiral Pyrrolidine Isostere Inserted into Pyrrole Polyamide Skeleton. J Chin Chem Soc 2012, 59:436-442.
• [11]Wall DP, Tonellato PJ: The future of genomics in pathology. F1000 Med Rep 2012. in press
• [12]Osborne JD, Flatow J, Holko M, Lin SM, Kibbe WA, Zhu LJ, Danila MI, Feng G, Chisholm RL: Annotating the human genome with Disease Ontology. BMC Genomics 2009, 10:S6.
• [13]Sun G: Application of DNA microarrays in the study of human obesity and type 2 diabetes. OMICS 2007, 11:25-40.
• [14]Kurella M, Hsiao LL, Yoshida T, Randall JD, Chow G, Sarang SS, Jensen RV, Gullans SR: DNA microarray analysis of complex biologic processes. J Am Soc Nephrol 2001, 12:1072-1078.
• [15]Schnabel RB, Baccarelli A, Lin H, Ellinor PT, Benjamin EJ: Next steps in cardiovascular disease genomic research–sequencing, epigenetics, and transcriptomics. Clin Chem 2012, 58:113-126.
• [16]Rogers S, Girolami M, Kolch W, Waters KM, Liu T, Thrall B, Wiley HS: Investigating the correspondence between transcriptomic and proteomic expression profiles using coupled cluster models. Bioinformatics 2008, 24:2894-2900.
• [17]Dhingra V, Gupta M, Andacht T, Fu ZF: New frontiers in proteomics research: a perspective. Int J Pharm 2005, 299:1-18.
• [18]Greenbaum D, Colangelo C, Williams K, Gerstein M: Comparing protein abundance and mRNA expression levels on a genomic scale. Genome Biol 2003, 4:117. BioMed Central Full Text
• [19]Guo Y, Xiao P, Lei S, Deng F, Xiao GG, Liu Y, Chen X, Li L, Wu S, Chen Y, Jiang H, Tan L, Xie J, Zhu X, Liang S, Deng H: How is mRNA expression predictive for protein expression? A correlation study on human circulating monocytes. Acta Biochim Biophys Sin (Shanghai) 2008, 40:426-436.
• [20]Blattner FR, Plunkett G, Bloch CA, Perna NT, Burland V, Riley M, Collado-Vides J, Glasner JD, Rode CK, Mayhew GF, Gregor J, Davis NW, Kirkpatrick HA, Goeden MA, Rose DJ, Mau B, Shao Y: The complete genome sequence of Escherichia coli K-12. Science 1997, 277:1453-1462.
• [21]Butland G, Peregrín-Alvarez JM, Li J, Yang W, Yang X, Canadien V, Starostine A, Richards D, Beattie B, Krogan N, Davey M, Parkinson J, Greenblatt J, Emili A: Interaction network containing conserved and essential protein complexes in Escherichia coli. Nature 2005, 433:531-537.
• [22]Pandey A, Mann M: Proteomics to study genes and genomes. Nature 2000, 405:837-846.
• [23]Lockhart DJ, Winzeler EA: Genomics, gene expression and DNA arrays. Nature 2000, 405:827-836.
• [24]Nielsen J, Olsson L: An expanded role for microbial physiology in metabolic engineering and functional genomics: moving towards systems biology. FEMS Yeast Res 2002, 2:175-181.
• [25]Yoon SH, Han MJ, Lee SY, Jeong KJ, Yoo JS: Combined transcriptome and proteome analysis of Escherichia coli during high cell density culture. Biotechnol Bioeng 2003, 81:753-767.
• [26]Han MJ, Lee SY: The Escherichia coli proteome: past, present, and future prospects. Microbiol Mol Biol Rev 2006, 70:362-439.
• [27]Lee PS, Lee KH: Escherichia coli–a model system that benefits from and contributes to the evolution of proteomics. Biotechnol Bioeng 2003, 84:801-814.
• [28]Fu W, Yu Y, Xu L: Identification of temporal differentially expressed protein responses to microcystin in human amniotic epithelial cells. Chem Res Toxicol 2009, 22:41-51.
• [29]Jiang YL, Ning Y, Ma XL, Liu YY, Wang Y, Zhang Z, Shan CX, Xu YD, Yin LM, Yang YQ: Alteration of the proteome profile of the pancreas in diabetic rats induced by streptozotocin. Int J Mol Med 2011, 28:153-160.
• [30]Sala GL, Ronzitti G, Sasaki M, Fuwa H, Yasumoto T, Bigiani A, Rossini GP: Proteomic analysis reveals multiple patterns of response in cells exposed to a toxin mixture. Chem Res Toxicol 2009, 22:1077-1085.
• [31]Beal DR, Titball RW, Lindsay CD: The development of tolerance to Clostridium perfringens type D epsilon-toxin in MDCK and G-402 cells. Hum Exp Toxicol 2003, 22:593-605.
• [32]Bukau B, Horwich AL: The Hsp70 and Hsp60 chaperone machines. Cell 1998, 92:351-366.
• [33]Boshoff A, Nicoll WS, Hennessy F, Ludewig MH, Daniel S, Modisakeng KW, Shonhai A, McNamara C, Bradley G, Blatch GL: Molecular chaperones in biology, medicine and protein biotechnology. South African J Sci 2004, 100:665-677.
• [34]Turturici G, Sconzo G, Geraci F: Hsp70 and its molecular role in nervous system diseases. Biochem Res Int 2011, 2011:1-18.
• [35]Hay DG, Sathasivam K, Tobaben S, Stahl B, Marber M, Mestril R, Mahal A, Smith DL, Woodman B, Bates GP: Progressive decrease in chaperone protein levels in a mouse model of Huntington's disease and induction of stress proteins as a therapeutic approach. Hum Mol Genet 2004, 13:1389-1405.
• [36]Klucken J, Shin Y, Masliah E, Hyman BT, McLean PJ: Hsp70 Reduces alpha-Synuclein Aggregation and Toxicity. J Biol Chem 2004, 279:25497-25502.
• [37]Plumier JC, Krueger AM, Currie RW, Kontoyiannis D, Kollias G, Pagoulatos GN: Transgenic mice expressing the human inducible Hsp70 have hippocampal neurons resistant to ischemic injury. Cell Stress Chaperones 1997, 2:162-167.